Head and neck cancer: gene therapy approaches.Part II: genes delivered

Bibliography

• SCHANTZ SP, SHILLITOE EJ, BROWN B et al.: Natural killer cell activity and head and neck cancer: A clinical assessment. Natl. Cancer Inst. (1986) 77:869–875.
   Google Scholar
• WANEBO HJ, BLACKINTON D, TURK P et al.: Augmentation of the LAK cell response in head and neck neoplasms by combination IL-2 and INF-alpha. Am. &mg. (1991) 162:384–387.
   Web of Science ®Google Scholar
• WANEBO HJ, BLACKINTON D, KOUTTAB N etal.: Contribution of serum inhibitory factors and immune cellular defects to the depressed cell mediated immunity patients with head and neck cancer. Am. J. &mg. (1993) 166:389–394.
   Google Scholar
• CLAYMAN GL, TAYLOR DL, LIU FJ et al.: Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells. Laryngoscope (1993) 103:299–307.
   PubMed Web of Science ®Google Scholar
• TAS MP, SIMONS PJ, BALM FJ et al.: Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol Immunother (1993) 36:108–114.
   PubMed Web of Science ®Google Scholar
• GALLO O, BIANCHI S, GIANNINI A et al.: Correlations between histopathological and biological findings in nasopharyngeal carcinoma and its prognostic significance. Laryngyscope (1991) 101:487–493.
   PubMed Web of Science ®Google Scholar
• ZONG YS, ZHANG CO, ZHANG F et al: Infiltrating lymphocytes and accessory cells in nasopharyngeal carcinoma. hm. j Cancer Res. (1993) 84:900–905.
   PubMed Web of Science ®Google Scholar
• BEUCHLER M, MUCKHERJI B, CHASIN W etal.: High dose methotrexate with and without BCG therapy in advanced head and neck malignancy. Cancer (1979) 43:1095–1100.
   Google Scholar
• PAPAC R, MINOR DR, RUDNICK S etal.: Controlled trial of Methotrexate and bacillus Calmette-Guerin therapy for advanced head and neck cancer. Cancer Res. (1978) 38:3150–3153.
   Google Scholar
• CUNNINGHAM TJ, ANTEMANN R, PAONESSA D etal.: Adjuvant immuno and/or chemotherapy with neuaminidase-treated autogenous tumor vaccine and bacillus Calmette-Guerin for head and neck cancers. Ann. NY Acad. ScL (1976) 277:339–344.
   Google Scholar
• TAYLOR SG, SISSON GA, BYTELL DE:Adjuvant chemoimmunotherapy of head and neck cancer. Recent Results Cancer Res. (1979) 68:297–308.
   Google Scholar
• SACHI M, SNYDERMAN CH, HEO DS et al.: Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine activated killer cells and IL-2. Cancer Res. (1990) 50:3113–3118.
   PubMed Web of Science ®Google Scholar
• WHITESIDE TL, LETESSIER E, HIRABAYASHI H et al.: Evidence for local and systemic activation of immune cells by peritumoral injections of IL-2 in patients with advanced head and neck cancer. Cancer Res. (1993) 53:5654–5662.
   PubMed Web of Science ®Google Scholar
• CORTESINA G, DE STEFANI A, GIOVARELLI M et al.: Treatment of recurrent squamous cell carcinoma of the head and neck with low does of IL-2 injected perilymphatically. Cancer (1988) 61:2482–2485.
   Google Scholar
• SLATER J, MACLENAN KA, MOORE J etal.: The phenotypic changes in tumor infiltrating lymphocytes and tumor cells following intra-arterial infusion of IL-2 in patients with squamous cell carcinoma. j Pathol. (1995) 176:167–173.
   Google Scholar
• DE STEFANI A, VALENTE G, FORNI G et al.: Treatment of oral cavity and otopharynx squamous cell carcinoma with perilymphatic IL-2: Clinical and pathologic correlation. j brununother. (1995) 19:125–133.
   Google Scholar
• RICHMAN SP, LIVINGSTON RB, GUTTERMAN JU et al.: Chemotherapy versus chemo-immunotherapy of head and neck cancer: Report of a randomized study. Cancer Treat. Rep. (1976) 60:535–539.
   PubMedGoogle Scholar
• AMIEL JL, SANCHO-GARNIER H, VANDERBROUCK C et al.: First results of a randomized trial on immunotherapy of head and neck tumors. Recent Results Cancer Res. (1979) 68:318.
   Google Scholar
• TAYLOR SG, RAYNOR WJJ, BYTELL DE et al.: A randomized trial of adjuvant BCG immunotherapy in head and neck cancer. Arch. Otolaryngol (1983) 109:544–549.
   PubMed Web of Science ®Google Scholar
• WHITESIDE TL, CHIKAMATSU K, NAGASHIMA S et al.: Antitumor effects of cytolytic T-lymphocytes (CU) and natural killer (NK) cells in head and neck cancer. Anticancer Res. (1996) 16:2357–2364.
   PubMed Web of Science ®Google Scholar
• SACHI M, VITOLO D, SEDELMAYR P et al.: Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2. Intl Cancer (1991) 47:784–791.
   PubMed Web of Science ®Google Scholar
• RABINOWICH H, VITOLO D, ALTARAC S et al.: Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2 activated natural killer cells. Immunol (1993) 149:340–349.
   Web of Science ®Google Scholar
• KITA KH, TACHIKAWA SS, HORI Y et al.: Inhibition of head and neck tumor cell colony growth by lymphokine activated killer cells. Acta Otolaryngol Suppl (Stockholm) (1993) 500:138–141.
   PubMedGoogle Scholar
• YASAMURA S, HIRABAYASHI H, SCHWARZ D et al.: Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res. (1993) 53:1461–1468.
   PubMed Web of Science ®Google Scholar
• SQUADRELLI-SARACENO M, RIVOLTINI L, CANTU G et al: Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and IL-2. Tumor (1990) 76:566–571.
   PubMed Web of Science ®Google Scholar
• IWAKA T, EURA M, FUKIAGE T et al.:Adoptive immunotherapy by intra-arterial infusion of ATLAK or allo-TLAK cells in patients with head and neck cancer. Can To Kaguku Ryoho (1989) 16:1438–1447.
   PubMedGoogle Scholar
• ADDISON CL, BRACIAK T, RALSTON R eta].: Intratumoral injection of an adenovirus expressing IL-2 induced regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sri. USA (1995) 92:8522–8526.
   Google Scholar
• TOLOZA EM, HUNT K, SWISHER S et al.: In vivo cancer gene therapy with a recombinant IL-2 adenovirus vector. Cancer Gene Ther. (1996) 3(1):11–17.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• O'MALLEY BWJ, COPE KA, CHEN SH et al.: Combination gene therapy for oral cancer in a murine model. Cancer Res. (1996) 56:1737–1741.
   PubMedGoogle Scholar
• O'MALLEY BW, SEWELL DA, LI D et al.:The role of IL-2 in combination adenovirus gene therapy for head and neck cancer. Mol. Endocrinol. 11:667–673.
   Google Scholar
• O'MALLEY BW, LID, BUCKNER A et al.: Limitation of adenovirus-mediated IL-2 gene therapy for oral cancer. Laryngoscope (1999) 109:389–395.
   Google Scholar
• LID, JIANG W, BISHOP JS etal.: Combination surgery and nonviral IL-2 gene therapy head and neck cancer. Clin. Cancer Res. (1999) 5:1551–1556.
   Google Scholar
• MYERS JN, MANK-SEYMOUR A, ZITVOGEL L et al: Interleukin-2 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope (1998) 108:261–268.
   PubMed Web of Science ®Google Scholar
• O'MALLEY BW, COPE KA, JOHNSON CS et al.: A new immunocompetent murine model for oral cancer. Arch. Otolaryngol. Head Neck Surg. (1997) 123:20–24.
   PubMed Web of Science ®Google Scholar
• LID, DUAN L, FREIMUTH P, O'MALLEY BW JR: Variability of adenovirus receptor density influences gene tran efficiency and therapeutic response in head and neck cancer. Clin. Cancer Res. (1999) 5(12):4175–4181.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• VILE RG, NELSON JA, CASTLEDEN S, CHONG H, HART IR: Systemic gene therapy of murine melanoma using tissue specific expression of the HSV-tk gene involves an immune component. Cancer Res. (1994) 54:6228–6234.
   PubMed Web of Science ®Google Scholar
• MIZUNO H, YANOMA S, NISHIMURA G et al.: Therapeutic efficiency of IL-2 gene transduced tumor vaccine for head and neck carcinoma. Cancer Lett. (2000) 152:175–185.
   PubMed Web of Science ®Google Scholar
• DAY KV, LI D, LIU S, GUO M, O'MALLEY BW JR.: Granulocyte-macrophage colony-stimulating factor in a combination gene therapy strategy for head and neck cancer. Laryngoscope (2001) 111:801–806.
   Google Scholar
• LANG S, ZEIDLER R, MAYER A, REIMAN V, WOLLENBERG B, KASTENBAUER E: Targeting head and neck cancer by GM-CSF-mediated gene therapy in vivo. Anticancer Res. (1999) 19:5335–5340.
   PubMed Web of Science ®Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY A et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Nati Acad. Li. USA (1993) 90:3539–3543.
   PubMed Web of Science ®Google Scholar
• ••Article of special interest.
   Google Scholar
• NEMUNAITIS J, STERMAN D, JABLONS J et al.: A phase I/II study of autologous GM-CSF gene-modified cancer vaccines in subjects with non-small cell lung cancer (NSCLC). Proc. ASCO (2001) 20:255a.
   Google Scholar
• SIMONS JW, SMALL E, NELSON W et al.: Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) demonstrated anti-tumor activity. Proc. ASCO (2001) 20:269a.
   Google Scholar
• MUTLU S, MATTHEWS JB, MIDDA M et al.: MHC antigen expression in human oral squamous carcinoma cell lines. Pathol. (1991) 165:129–136.
   Web of Science ®Google Scholar
• HOUCK JR, SEXTON FM, ZAJDEL G: HLA class I and class II antigen expression on squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. (1990) 116:1181–1185.
   PubMed Web of Science ®Google Scholar
• BORING CC, SQUIRES TS, TONG T: Cancer Statistics. Cancer j Clin. (1994) 44:7–26.
   PubMed Web of Science ®Google Scholar
• MYERS EN, SUEN JY (Eds.): Cancer of theHead and Neck. Third Edition. (1996) WB Saunders Co., Philadelphia, PA, USA.
   Google Scholar
• HOUCK JR, SHAH TP, OHLSSON-WILHELM BM et al.: Modulation of human leukocyte antigen class I expression by gamma interferon in head and neck cancer cell lines. Am. j Otolaryngol. (1988) 9:217–223.
   PubMed Web of Science ®Google Scholar
• ESTEBAN F, CONCHA, DELGADO M et al.: Lack of MHC class I antigens and tumors aggressiveness of the squamous cell carcinoma of the larynx. Br. j Cancer (1990) 62:1047–1051.
   PubMed Web of Science ®Google Scholar
• PRIME SS, PITIGALA-ARACHI A, CRANE IJ etal.: The expression of cell surface MHC class I heavy and light chain molecules in premalignant and malignant lesions of the oral mucosa. Histopathology (1987) 11:81–91.
   Google Scholar
• MATIESEN V, DE MULDER PHM, SCHALVIJK L et al: HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites. Int. j Cancer (1991) 6:95–100.
   Google Scholar
• CRYSTAL RG: Transfer of genes to humans: Early lessons and obstacles to success. Science (1995) 270:404–410.
   PubMed Web of Science ®Google Scholar
• SACKS PG, TAYLOR DL, RACZ T et al.: A multi-cellular tumor steroid model of cellular immunity against head and neck cancer. Cancer Immunol. Immunother. (1990) 32:195–200.
   PubMed Web of Science ®Google Scholar
• AROSARENA OA, BARANWAL S, STROME S et al.: Expression of major histocompatibility complex antigens in squamous cell carcinomas of the head and neck: Effects of interferon gene transfer. Otolaryngol. Head Neck Surg. (1999) 120(5):666–671.
   Google Scholar
• MATTHEWS JB, PITIGALA-ARACHCHI A, CRANE IJ et al.: The relationship between epithelial Ia expression and the inflammatory cell infiltrate during experimental oral carcinogenesis. Virchows Arch. A Pathol. Anat. Histopathol. (1988) 413:521–528.
   PubMedGoogle Scholar
• NEMUNAITIS J, KUHN J: Immune modulation as cancer treatment using gene therapy. BUMC Proc. (1999) 12:231–237.
   Google Scholar
• NEMUNAITIS J, FONG T, EDELMAN G et al.: Phase I trial of gamma-interferon (y-IFN) retroyiral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther. (1999) 6(4):322–330.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, FONG T, BURROWS Fet al.: Phase I trial of gamma-interferon (7-IFN) retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma. Hum. Gene Ther. (1999) 10(8):1289–1298.
   Google Scholar
• FUJII S, HUANG S, FONG TC et al.: Induction of anti-melanoma-associated antigen systemic immunity on intratumor delivery of interferon-y retroviral vector in melanoma patients. Gene Ther In press.
   Google Scholar
• DE PLAEN E, ARDEN K, TRAVERSARI C: Structure, chromosome location and expression of 12 genes of the MAGE family. Immunogenetics (1994) 40:360–369.
   PubMed Web of Science ®Google Scholar
• VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T-lymphocytes on a human melanoma. Science (1991) 254:1643–1647.
   Google Scholar
• DE SMET C, LURQUIN C, VAN DER BRUGGEN P et al.: Sequence and expression pattern of human the MAGE2 gene. Immunogenetics (1994) 39:121–129.
   Google Scholar
• BRASSEUR F, MARCHAND M, VAN WIJCK R: Human gene MAGE-1, which codes for a tumor rejection antigen, is expressed by some breast tumors. Int. Cancer (1992) 52:839–841.
   PubMed Web of Science ®Google Scholar
• EURA M, OGI K, CHIKAMATSU K et al.: Expression of the MAGE gene family in human head and neck squamous cell carcinoma. Int. j Cancer (1995) 64:304–308.
   PubMed Web of Science ®Google Scholar
• SOUSSI T, LEGROS Y, LUBIN R etal.: Multifactorial analysis of p53 alteration in human cancer: A review. Int. j Cancer (1994) 57:1–9.
   Google Scholar
• CIERNIK IF, BERZOFSKY JA, CARBONE DP: Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. Hybridoma (1995) 14:139–142.
   PubMed Web of Science ®Google Scholar
• LEE CT, CIERNIK IF, WU S et al: Increased immunogenicity of tumors bearing mutant p53 and P lA epitopes after transduction of B7-1 via recombinant adenovirus. Cancer Gene Ther (1996) 3:238–244.
   PubMed Web of Science ®Google Scholar
• ROPKE M, HALD J, GULDBERG P et al.: Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T-lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Li. USA (1996) 93:14704–14707.
   PubMed Web of Science ®Google Scholar
• GLEICH LL, GLUCKMAN JL, ARMSTRONG S et al.: Alloantigen gene therapy for squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. (1998) 124:1097–1104.
   PubMed Web of Science ®Google Scholar
• GLEICH LL, GLUCKMAN JL, NEMUNAITIS J et al: Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. (2001) 127:775–779.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• DUBEY C, CROFT M, SWAIN SL: Costimulatory requirements of naïve CD4+ T cells, ICAM-1 or B7.1 can costimulate naïve CD4+ T cell activation but both are required for optimum response. I Immunol. (1995) 155:45–47.
   Google Scholar
• GUINAN EC, GRIBBEN JG, VICKI AB, FREEMAN GJ, NADLER LM: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood (1994) 10:3261–3282.
   Google Scholar
• DUBEY C, CROFT M, SWAIN SL: Costimulatory requirements of naïve CD4+ T-cells, ICAM-1 or B7.1 can costimulate naïve CD4+ T-cell activation but both are required for optimum response. I Immunol. (1995) 155:45–47.
   Google Scholar
• GUINAN EC, GRIBBEN JG, VICKI AB et al.: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood (1994) 10:3261–3282.
   Google Scholar
• RANHEIM EA, KIPPS TJ: Activated T-cells induce expression of B7/BB1 on normal or leukemic B-cells through a CD40-dependent signal. j Exp. Med. (1993) 177:925–935.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, BAZAN F, BLANCHARD D etal.: The CD40 antigen and its ligand. Ann. Rev Immunol. (1994) 12:881–922.
   Google Scholar
• DOHRING C, ANGMAN L, SPANGNOLI G et al.: T-helper and accessory cell independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int. j Cancer (1994) 57:754–759.
   PubMed Web of Science ®Google Scholar
• BAIN C, MERROUCHE Y, PUISIEUX I et al.: B7.1 gene transduction of human renal cell carcinoma cell lines restored the proliferative response and cytotoxic function of allogeneic T-cells. Int. j Cancer (1996) 67:769–776.
   Google Scholar
• TOWNSEND SE, ALISON JP: Tumor rejection after direct costimulation of CD8+ T-cells by B7-transfected melanoma cells. Science (1993) 259:368–370.
   PubMed Web of Science ®Google Scholar
• ROTH JA, CRISTIANO RJ: Gene therapyfor cancer: What have we done and where are we going?j Natl. Cancer Inst. (1997) 88:21–39.
   Google Scholar
• TODARO GJ, DE LARCO JE: Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells. Nature (1976) 264:26–31.
   PubMed Web of Science ®Google Scholar
• TODARO GJ, FRYLING C, DE LARCO JE: Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc. Natl. Acad. Sri. USA (1980) 77:5258–5262.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL A, LINDQUIST PB, BRINGMAN TS, GOEDDEL DV, DERYNCK R: Expression in rat fibroblasts of a human transforming growth factor-alpha cDNA results in transformation. Cell (1986) 46:301–309.
   PubMed Web of Science ®Google Scholar
• ENDO S, ZENG Q, BURKE NA et al.: TGF-ot antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo. Gene Ther. (2000) 7:1906–1914.
   PubMed Web of Science ®Google Scholar
• DI MARCO E, PIERCE JH, FLEMING TP et al: Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene (1989) 4:831–838.
   PubMed Web of Science ®Google Scholar
• MORONI MC, WILLINGHAM MC, BEGUINOT L: EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. j Biol. Chem. (1992) 267:2714–2722.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• SOLORZANO CC, JONES SC, PETTITJEAN M etal.: Inhibition of transforming growth factor alpha stimulation of human squamous cell carcinoma of the head and neck with anti-TGF-alpha antibodies and tyrphostin. Ann. Surg. Oncol. (1997) 4:670–678.
   Google Scholar
• •Article of interest.
   Google Scholar
• LAIRD AD, BROWN PI, FAUSTO N: Inhibition of tumor growth in liver epithelial cells transfected with a transforming growth factor alpha antisense gene. Cancer Res. (1994) 54:4224–4232.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, CHAKRABORTY A,ZENG Q, MELHEM MF, TWEARDY DJ et al.: Downmodulation of the TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous cell carcinoma but not normal mucosal epithelial cells. j Cell Biochem. (1998) 69:55–62.
   Google Scholar
• GERUTTI PA: Pro-oxidant state and tumor promotion. Science (1985) 227:375–381.
   PubMedGoogle Scholar
• OBERLY LW: Superoxide dismutase and cancer. In: Superoxide Dismutase. Oberly LW (Ed.), CRC Press, Boca Raton, Florida, USA (1982):127–165.
   Google Scholar
• ZHONG W, OBERLY LW, OBERLEY TD et al.: Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oricogene (1997) 14:481–490.
   PubMed Web of Science ®Google Scholar
• TRENT JM, STANDBRIDGE EJ, MCBRIDE HL etal.: Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science (1990) 247:568–571.
   Google Scholar
• CHURCH SL, GRANT JW, RIDNOUR LA etal.: Increased manganese dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc. Natl. Acad. Sci. USA (1993) 90:3113–3117.
   Google Scholar
• LI J: Inhibition of growth of human oral cancer cells by transfection of MnSOD cDNA. MS Thesis, The University of Iowa, USA (1995).
   Google Scholar
• YAN T, OBERLEY LW, ZHONG WX et al.: Manganese-containing superoxide dismutase overexpression causes phenotypic reversion in SV-40-transformed human lung fibroblasts. Cancer Res. (1996) 56:2864–2871.
   PubMed Web of Science ®Google Scholar
• LIU R, OBERLEY TD, OBERLEY LW: Transfection and expression of MnSOD cDNA decreases tumor malignancy of human oral squamous carcinoma SCC-25 cells. Human Gene Ther. (1997) 8:585–595.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• LAM EWN, HAMMAD HM, ZWACKA R etal.: Immunolocalization and adenoviral vector-mediated manganese superoxide dismutase gene transfer to experimental oral tumors. J. Dent. Res. (2000) 79(6): 1410–1417.
   Google Scholar
• GRIENDLING KK, MINIERI CA, OLLERENSHAW JD, ALEXANDER RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. (1994) 74:1141–1148.
   PubMed Web of Science ®Google Scholar
• LO YYC, WONG JMS, CRUZ TF: Reactive oxygen species mediate cytokine activation of c-Jun NH2-terminal kinases. Biol. Chem. (1996) 271:15703–15707.
   Web of Science ®Google Scholar
• CUI XL, DOUGLAS JG: Arachidonic acid activates c-Jun N-terminal kinase through NADPH oxidase in rabbit proximal tubular epithelial cells. Proc. Nati Acad. Li. USA (1997) 94:3771–3776.
   PubMed Web of Science ®Google Scholar
• WONG GH, GOEDDEL DV: Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science (1988) 242:941–944.
   PubMed Web of Science ®Google Scholar
• FISCHER C, BOND CP: The quantimet 720D for densitometry in the life sciences. Microscope (1972) 20:203–216.
   Web of Science ®Google Scholar
• TAKAHASHI H, HASHIMOTO Y, KINOUCHI M, IZUKA H: Interferon-gamma-dependent induction of manganese superoxide dismutase activity of 5V40-transformed human keratinocytes by anti-Fas antibody and by TNF-alpha. Dermatol Sci. (1998) 16:191–199.
   PubMed Web of Science ®Google Scholar
• COUKOS G, RUBIN SC: Gene therapy for ovarian cancer. Oncology (2001) 15:1197–1207.
   PubMed Web of Science ®Google Scholar
• CHENG YC, GRILL SP, DUTSCHMAN GE et al.: Metabolism of 9- (1,3-dihydroxy-2-proposymethyl) guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. j Biol. Chem. (1983) 258:12460–12464.
   PubMed Web of Science ®Google Scholar
• O'MALLEY BW JR, CHEN S-H, SCHWARTZ MR et al.: Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. (1995) 55:1080–1085.
   Google Scholar
• ••Article of special interest.
   Google Scholar
• GOEBEL EA, DAVIDSON BL, GRAHAM SM et al.: Tumor reduction in vivo after adenoviral mediated gene transfer of the herpes simplex virus thymidine kinase gene and Ganciclovir treatment in human head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. (1998) 119(4):331–336. ma. THOMAS SM, NARESH KN, WAGLE AS et al: Preclinical studies on suicide gene therapy for head/neck cancer: A novel method for evaluation of treatment efficacy. Anticancer Res. (1998) 18:4393–4398.
   Google Scholar
• SEWELL DA, LI D, DUAN L et at Optimizing suicide gene therapy for head and neck cancer. Laryngoscope (1997) 107:1490–1495.
   PubMed Web of Science ®Google Scholar
• WILSON KM, STAMBROOK PJ, BI WL et al.: HSV-tk gene therapy in head and neck squamous cell carcinoma: enhancement by the local and distant bystander effect. Arch. Otolaryrigol Head Neck Surg. (1996) 122:746–749.
   PubMed Web of Science ®Google Scholar
• MORRIS JC, WILDNER O: Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mal Ther. (2000) 1:56–62.
   PubMed Web of Science ®Google Scholar
• FUKUI T, HAYASHI Y, KAGAMI H et al: Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector. Oral Oricol (2001) 37:211–215.
   PubMed Web of Science ®Google Scholar
• ROGULSKI KR, WING MS, PAIELLI DL, GILBERT JD, KIM JH, FREYTAG SO: Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther. (2000) 11:67–76.
   PubMed Web of Science ®Google Scholar
• FREYTAG SO, ROGULSKI KR, PAIELLI DL, GILBERT JD, KIM JH: An novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther (1998) 9:1323–1333.
   PubMed Web of Science ®Google Scholar
• SINGH S, CUNNINGHAM C, BUCHANAN A, JOLLY DJ, NEMUNAITIS J: Toxicity assessment of intratumoral injection of retroviral delivered herpes simplex type I thymidine kinase (HSV-TK) gene in patients with refractory cancer. Mol. Ther. (2001) 4:157–160.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• CALABRESI P, CHABNER BA: Antineoplastic agents. In: Goodman and Gilman 's The Pharmacological Basis of Therapeutics. Eighth Edition. Gilman AG, Rall T, Nies AS, Taylor P (Eds.) Pergamon Press, New York, USA (2000):1209–1263.
   Google Scholar
• OHWADA A, HIRSHOWITZ EA, CRYSTAL RG: Regional delivery of an adenovirus vector containing the E. coil cytosine deaminase to suppress the growth of colon carcinoma metastatic to the liver. Hum. Gene Ther. (1996) 8:73–85.
   Google Scholar
• DONG Y, WEN P, MANOME Y et al.: In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum. Gene Ther (1996) 7:713–720.
   PubMed Web of Science ®Google Scholar
• HIRSCHOWITZ EA, OHWADA A, PASCAL WR, RUSSI TJ, CRYSTAL RG: In vivo adenovirus-mediated gene transfer of the Escherichia coil cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum. Gene Ther. (1995) 6:1055–1063.
   PubMed Web of Science ®Google Scholar
• SANDALON Z, FUSENIG NE, MCCUTCHEON J, TAICHMAN LB, GARLICK JA: Suicide gene therapy for premalignant disease: a new strategy for the treatment of intraepithelial neoplasia. Gene Ther. (2001) 8:232–238.
   PubMed Web of Science ®Google Scholar
• KATO J, MATSUSHIME H, HIEBERT S et al.: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. (1993) 7:331–342.
   PubMed Web of Science ®Google Scholar
• MULLER D, MILLON R, LIDEREAU R et al.: Frequent amplification of 11q13 DNA markers is associated with lymph node involvement in human head and neck squamous cell carcinoma. Eur. j Cancer B. Oral Oricol. (1994) 30B:113–120.
   PubMed Web of Science ®Google Scholar
• MICHALIDES R, VAN VEELEN N, KRISTEL P et al.: Over-expression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch. Otolarygol. Head Neck &mg. (1997) 123:497–502.
   PubMed Web of Science ®Google Scholar
• TAKES R, DE JONG R, SCHUURING E et al.: Markers of assessment of nodal metastasis in laryngeal carcinoma. Arch. Otolaryrigol. Head Neck &mg. (1997) 123:412–419.
   PubMed Web of Science ®Google Scholar
• KORNMANN M, ARBER N, KORC M: Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin Dlantisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. j Chu. Invest. (1998) 101:344–352.
   PubMed Web of Science ®Google Scholar
• DRISCOLL B, WU L, BUCKLEY S etat.: Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth. Am. Physiol. (1997) 23:L941–949.
   Google Scholar
• HUNG WC, HUANG JS, CHUANG LY: Antisense oligodeoxynucleotides targeted against regions of cyclin D1 mRNA may exert different inhibitory effects on cell growth and gene expression. Biochem. Biophys. Res. Commun. (1996) 220:719–723.
   PubMed Web of Science ®Google Scholar
• SCHRUMP DS, CHEN A, CONS OLI U: Inhibition of lung cancer proliferation by antisense cyclin Dl. Cancer Gene Ther. (1996) 3:131–135.
   PubMed Web of Science ®Google Scholar
• ZHOU P, JIANG W ZHANG YJ etal.: Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oricogerre (1995) 11:571–580.
   Google Scholar
• SAUTER ER, NESBIT M, LITWIN S et al.: Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous cell carcinomas. Cancer Res. (1999) 59:4876–81.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• WANG SJ, MINTZ LE, NATARAJAN V et al.: Third place - resident research competition, AAO-2000. Antisense cyclin D1 inhibits growth of head and neck cancer xenografts in nude mice. Otolaryrigol. Head Neck Surg. (2001) 124:656–662.
   Google Scholar
• NAKASHIMA T, CLAYMAN G: Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck &mg. (2000) 126:957–961.
   PubMed Web of Science ®Google Scholar
• ADAMS JM, COREY S: The bc1-2 protein family: arbiters of cell survival. Science (1998) 281:1322–1326.
   PubMed Web of Science ®Google Scholar
• SEITE P, HILLION J, D'AGAY MF et al.: BCL2 gene activation and protein expression in follicular lymphoma: a report on 64 cases. Leukemia (1993) 7:410–417.
   Google Scholar
• HALDAR S, NEGRINI M, MONNE M, SABBIONI S, CROCE CM: Down-regulation of bc1-2 by p53 in breast cancer cells. Cancer Res. (1994) 54:2095–2097.
   PubMed Web of Science ®Google Scholar
• REED JC, MEISTER L, TANAKA S et al.: Differential expression of bc12 proto-oncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res. (1991) 51:6529–6538.
   PubMed Web of Science ®Google Scholar
• STEFANAKI K, RONTOGIANNIS D, VAMVOUKA C et al: Immunohistochemical detection of bc12, p53, mdm2, and p21/wafl proteins in small-cell lung carcinomas. Anticancer Res. (1998) 18:1689–1695.
   PubMed Web of Science ®Google Scholar
• VALASSIADOU KE, STEFANAKI K, TZARDI M et al: Immunohistochemical expression of p53, bc12, mdm2 and wafl/ p21 proteins in colorectal adenocarcinomas. Anticancer Res. (1997) 17:2571–2576.
   PubMed Web of Science ®Google Scholar
• JORDAN RC, CATZAVELOS GC, BARRETT AW, SPEIGHT PM: Differential expression of bc1-2 and bax in squamous cell carcinomas of the oral cavity. Oral °rico]. (1996) 32:394–400.
   Google Scholar
• DRACHENBERG CB, BLANCHAERT R, IOFFE OB, ORD RA, PAPADIMITRIOU JC: Comparative study of invasive squamous cell carcinoma and verrucous carcinoma of the oral cavity: expression of bc1-2, p53, and her-2/neu, and indexes of cell turnover. Cancer Detect. Prevent. (1997) 21:483–489.
   PubMedGoogle Scholar
• SINGH BB, CHANDLER FW, WHITAKER SB, FORBES-NELSON AE: Immunohistochemical evaluation of bc1-2 oncoprotein in oral dysplasia and carcinoma. Oral Surg. Med. Pathol. (1998) 85:692–698.
   Google Scholar
• YAO L, IWAI M, FURATA I: Correlations of bc1-2 and p53 expression with the clinicopathological features in tongue squamous cell carcinomas. Oral. °rico]. (1999) 35:56–62.
   Google Scholar
• REED JC, CUDDY M, HALDAR S etal.: BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc. Nati Acad. Sci. USA (1990) 87:3660–3664.
   Google Scholar
• COTTER FE, JOHNSON P, HALL P et al.: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oricogerre (1994) 9:3049–3055.
   Google Scholar
• GIBSON SA, PELLENZ C, HUTCHISON RE, DAVEY FR, SHILLITOE EJ. Induction of apoptosis in oral cancer cells by an anti-bc1-2 ribozyme delivered by an adenovirus vector. Chu. Cancer Res. (2000) 6:213–222.
   Google Scholar
• YU D, SUEN TC, YAN DH, CHANG LS, HUNG MC: Transcriptional repression of the neu proto-oncogene by the adenovirus 5 ElA gene products. Proc. Natl. Acad. Sci. USA (1990) 7:4499–4503.
   Google Scholar
• YU D, SCORSONE K, HUNG MC: Adenovirus type 5 ElA gene products act as transformation suppressors of the neu oncogene. Mol. Cell Biol. (1991) 11:1745–1750.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, YU D, XIA W, HUNG MC: Her-2/neu-targeting cancer therapy via adenovirus-mediated ElA delivery in an animal model. Oricogerre (1995) 10: 1947-1954.
   Google Scholar
• YAN DH, CHANG LS, HUNG MC: Repressed expression of the HER-2/c-erb-2 proto-oncogene by the adenovirus ElA gene products. Oricogerre (1991) 6:343–345.
   Google Scholar
• FRISCH SM, DOLTER EK: Adenovirus El a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism. Cancer Res. (1995) 55:5551–5555.
   PubMed Web of Science ®Google Scholar
• FRISCH SM: Antioncogenic effect of adenovirus ElA in human tumor cells. Proc. Nati Acad. Sci. USA (1991) 88:9077–9081.
   PubMed Web of Science ®Google Scholar
• UENO NT, BARTHOLOMEUSZ C, HERRMANN JL et al.: E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Chu. Cancer Res. (2000) 6:250–259.
   Google Scholar
• UENO NT, YU D, HUNG MC: Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene (1997) 15:953–960.
   PubMed Web of Science ®Google Scholar
• LOWE SW, RULEY HE, JACKS T, HOUSMAN DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 74:957–967.
   PubMed Web of Science ®Google Scholar
• DENG J, XIA W, HUNG MC: Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene (1998) 17:2167–2175.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• DUQUE PM, ALONSO C, SANCHEZ-PRIETO R et al.: Adenovirus lacking the 19-kDa and 55-kDa ElBgenes exerts a marked cytotoxic effect in human malignant cells. Cancer Gene Ther. (1999) 6:554–563.
   PubMed Web of Science ®Google Scholar
• MARCHETTI E, ROMERO J, SANCHEZ R etal.: Oncogenes and cellular sensitivity to radiotherapy. A study on murine keratinocytes transformed by v-H-ras, v-myc, v-neu, adenovirus ElA and mutant p53. Intl Oncol (1994) 5:611–618.
   Google Scholar
• SANCHEZ-PRIETO R, QUINTANILLA M, CANO A et al: Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E lA gene. Oncogene (1996) 13:1083–1092.
   PubMed Web of Science ®Google Scholar
• SHAO R, HU MC, ZHOU BP et al.: ElA sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of I kappaB kinases and nuclear factor kappaB activities. J. Biol. Chem. (1999) 274:21495–21498.
   PubMed Web of Science ®Google Scholar
• SHAO R, KARUNAGARAN D, ZHOU BE LI K etal.: Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. j Biol. Chem. (1997) 272:32739–32742.
   Google Scholar
• YU D, MATIN A, XIA W, SORGI F, HUANG L, HUNG MC: Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that over-express HER-2/neu. Oncogene (1995) 11:1383–1388.
   PubMed Web of Science ®Google Scholar
• GAO X, HUANG L: A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun. (1991) 179:280–285.
   PubMed Web of Science ®Google Scholar
• NABEL GJ, NABEL EG, YANG ZY et al.: Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sd. USA (1993) 90:11307–11311.
   PubMed Web of Science ®Google Scholar
• CAPLEN NJ, ALTON EW, MIDDLETON PG et al.: Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. (Published erratum in Nat. Med. (1995) 1:272). Nat. Med. 1: 39–46.
   Google Scholar
• BAKER SJ, MARKOWITZ S, FEARON E et al.: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 249:912–915.
   PubMed Web of Science ®Google Scholar
• HARPER JW, ADAMI GR, WEI N et al.: The p21 Cdk-interacting protein Cip2 is a potent inhibitor of G1 cyclin-dependent kinase. Cell (1993) 75:805–816.
   PubMed Web of Science ®Google Scholar
• MIYASHITA T, REED JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 80:293–299.
   PubMed Web of Science ®Google Scholar
• DAMERON K, VOPERT OV, TAINSKY MA et al.: Control of angiogenesis in fibroblast by p53 regulation of thrombospondin-1. Science (1994) 265:1582–1584.
   PubMed Web of Science ®Google Scholar
• DRACH J, ACKERMANN J, FRITZ E et al.: Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood (1998) 3:802–809.
   Google Scholar
• HORIO Y, TAKAHASHI T, KUROISHI T et al: Prognostic significance of p53 mutations and 3p deletion in primary resected non-small cell lung cancer. Cancer Res. (1993) 53:1.
   PubMed Web of Science ®Google Scholar
• THORALACIUS S, BORRESEN AL, EYFJORD JE: Somatic p53 mutations in human breast carcinomas in and Icelandic population, A prognostic factor. Cancer Res. (1993) 53:1637.
   PubMed Web of Science ®Google Scholar
• PREUDHOMME C, FENAUX P: The clinical significance of mutations of the p53 tumor suppressor gene in hematological malignancies. Br I Haematol (1997) 98:502.
   PubMed Web of Science ®Google Scholar
• LAI JL, PREUDHOMME C, ZANDECKI M et al.: Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia (1995) 9:370.
   Google Scholar
• HARRIS MP, SUTJPTO S, WILLS KN et al.: Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther. (1996) 2:121–129.
   Google Scholar
• WILLS KN, MANEVAL DC, MENZEL P et al.: Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther. (1994) 5:1079–1088.
   PubMed Web of Science ®Google Scholar
• Article of special interest.
   Google Scholar
• XU L, PIROLLO KF, CHANG EH: Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum. Gene Ther. (1997) 8:467–475.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• BLAGOSKLONNY MV, EL-DIRY WS: In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int. Cancer (1996) 67:386–392.
   PubMed Web of Science ®Google Scholar
• ZHANG W, ALEMANY R, WANG J eta/.: Safety evaluation of AdCMV-p53 in vitro and in vivo. Hum. Gene Ther. (1995) 6:155–164.
   Google Scholar
• ••Article of special interest.
   Google Scholar
• NGUYEN DM, SPITZ RF, YEN N et al: Gene therapy for lung cancer; Enhancement of tumor suppression by a combination of sequential systemic Cisplatin and adenovirus-mediated p53 gene transfer. Thor. Cardiovasc. Surg. (1996) 112(5):1372–1377.
   Web of Science ®Google Scholar
• PIROLLO KF, XU L, RAIT A et al.: Tumor-targeted sensitization to radiotherapy by systemically delivered WTp53. Am. Soc. Gene Ther. (1998) 379:95a. Abstract.
   Google Scholar
• NIELSEN LL, LIPARI P, DELL J, GURNANI, HAJIAN G: Adenovirus-mediated p53 gene therapy and Paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. (1998) 4:835–846.
   PubMed Web of Science ®Google Scholar
• ROTH JA, NGUYEN D, LAWRENCE DD et al.: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. (1996) 2(9):985–999.
   PubMed Web of Science ®Google Scholar
• SWISHER SG, ROTH JA, NEMUNAITIS J et al.: Adenoviral-mediated p53 gene transfer in patients with advanced non-small cell lung cancer (NSCLC). Proc. ASCO (1998) 17:431a. Abstract 1659.
   Google Scholar
• •Article of interest.
   Google Scholar
• NEMUNAITIS J, SWISHER SG, TIMMONS T etal.: Adenoviral mediated p53 gene transfer in sequence with Cisplatin to tumors of patients with non-small cell lung cancer. I Clin. Oncol (2000) 18(3):609–622.
   Google Scholar
• ••Article of special interest.
   Google Scholar
• CLAYMAN G, EL-NAGGAR AK, LIPPMAN SM et al: Adenoviral-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.Orical (1998) 16(6):2221–2232.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• WILSON DR, MERRITT JA, CLAYMAN G et al.: Clinical gene therapy strategies, Phase I/II results with adenoviral p53 (INGN 201) gene transfer in advanced head and neck and non-small cell lung cancer. Am. Soc. Gene Ther. (1998):96a. Abstract 380.
   Google Scholar
• NEMUNAITIS J, BIER-LANING CM, COSTENLA-FIGUEIRAS M et al: Three Phase II trials of intratumoral injection with a replication-deficient adenovirus carrying the p53 gene (Ad5CMV-p53) in patients with recurrent/refractory head and neck cancer. ASCO Proc. (1999) 18:431a. Abstract 1661.
   Google Scholar
• AGARVALA SS, VAN OSTEROM A, PETRUZULLI G et al.: Phase I study of rad/p53 in patients with advanced head and neck cancer (HNC). Proc ASCO (1998) 7:384a. Abstract 1470.
   Google Scholar
• CLAYMAN GL, DREILING LK: Injectable modalities as local and regional strategies for head and neck cancer. Hematal arca Chia. North Am. (1999) 13:787–810.
   PubMed Web of Science ®Google Scholar
• CLAYMAN GL, FRANK DK, BRUSO PA, GOEPFERT H: Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancer. OM. Cancer Res. (1999) 5:1715–1722.
   Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• BLACKWELL JL, MILLER CR, DOUGLAS JT et al.: Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch. Otalaryrigal Head Neck Surg. (1999) 125:856–863.
   PubMed Web of Science ®Google Scholar
• FRANK DK, LIU T-J, FREDERICK MJ, CLAYMAN GL: Combination of E2F-1 and p53 gene transfer does not enhance growth inhibition in human squamous cell carcinoma of the head and neck. Clin. Cancer Res. (1998) 4:2265–2272.
   PubMed Web of Science ®Google Scholar
• BISCHOFF JR, TURN DH, WILLIAMS A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274:373–376.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• NEMUNAITIS J, CUNNINGHAM C, BUCHANAN A et al.: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility, and biological activity. Celle Ther. (2001) 8:746–759.
   Google Scholar
• HEISE C, SAMPSON-JOHANNES A, WILLIAMS A et al.: ONYX-015, an ElB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. (1997) 3(6):639–645.
   PubMed Web of Science ®Google Scholar
• OLINER JD, KINZLER KW, MELTZER PS, GEORGE D, VOGELSTEIN B: Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature (1992) 358:80–83.
   PubMed Web of Science ®Google Scholar
• GOODRUM FD, ORNELLES DA. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle.j Viral. (1997) 71:584–561.
   Google Scholar
• HALL AR, DIX BR, O'CARROLL SJ, BRAITHWAITE AW: p53 dependent cell death/apoptosis is required for a productive adenovirus infection. Nat. Med. (1998) 4:1068–1072.
   PubMed Web of Science ®Google Scholar
• GANLY I, KIRN D, ECKHARDT SG et al.: A phase I study of Onyx-015, an ElB attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. OM. Cancer Res. (2000) 6:798–806.
   Web of Science ®Google Scholar
• RAJ K, OGSTON P, BEARD P: Virus-mediated killing of cells that lack p53 activity. Nature (2001) 412:914–917.
   PubMed Web of Science ®Google Scholar
• YOU L, YANG C-T, JABLONS DM: ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res. (2000) 60(4):1009–1013.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, KHURI F, GANLY I et al.: A phase II trial of intratumoral injection of ONYX-015 in patients with refractory head and neck cancer. j Clin. Orical (2001) 19:289–298.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• NEMUNAITIS J, GANLY I, KHURI F et at: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res. (2000) 60:6359–6366.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• NEMUNAITIS J, SENZER N, CUNNINGHAM C, DUBENSKY T: Commentary: Virus-mediated killing of cells that lack p53 activity. Drug Rests. Updates (2001). In press.
   Google Scholar
• KHURI F, NEMUNAITIS J, GANLY I et at: A controlled trial of intratumoral Onyx-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluororacil in patients with recurrent head and neck cancer. Nat. Med. 2000 6(8):879–885.
   PubMed Web of Science ®Google Scholar
• ••Article of special interest.
   Google Scholar
• FORASTIERE AA, METCH B, SCHULLER DE et al.: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a southwest oncology group study. Orical (1992)10:1245–1251.
   PubMed Web of Science ®Google Scholar
• JACOBS C, LYMAN G, VELEZ-GARCIA E etal.: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. j Clin. Orical (1992) 10:257–263.
   Google Scholar
• PAREDES J, HONG WK, FELDER TB et at: Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Orical (1988) 6(6):955–962.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• CLAVEL M, VERMORKEN JB, COGNETTI F et al.: Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin© in recurrent or metastatic squamous cell carcinoma of the head and neck. A Phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann. Orical (1994) 5:521–526.
   Google Scholar